Chemotherapy Triggers Gut Bacteria to Block Cancer Spread via Immune Rewiring

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide, and despite curative surgery plus adjuvant chemotherapy, 30–50% of patients develop distant metastases, predominantly in the liver. A major unanswered question has been whether chemotherapy-induced side effects — particularly intestinal mucositis — influence subsequent metastatic risk. This study, published in Nature Communications, provides a mechanistic answer: chemotherapy indirectly protects against liver metastasis by permanently reshaping the gut microbiome in a way that reprograms systemic immunity.

Using a clinically relevant mouse regimen of oxaliplatin (3.5 mg/kg) followed by 5-FU (50 mg/kg × 2 doses), the researchers confirmed that treatment caused intestinal mucositis — reduced crypt depth, villus length, and crypt cell proliferation in the small intestine within 3 days — while also suppressing tumor cell proliferation and inducing DNA double-strand breaks in implanted AKP colorectal tumor cells. Critically, when tumor cells were injected intraportally 14 days after chemotherapy (well after drug clearance), FO-pretreated mice developed significantly fewer and smaller liver metastases than controls, demonstrating an indirect, lasting 'chemomemory' effect independent of direct cytotoxicity.

Metabolomic profiling of plasma and cecal contents revealed that FO treatment dramatically elevated indole-3-propionic acid (IPA), a tryptophan-derived microbial metabolite, alongside shifts in gut microbiota composition — specifically expansion of IPA-producing bacteria including Clostridiales. Antibiotic depletion of the microbiome abolished both the IPA elevation and the metastasis-protective effect, confirming microbiota dependence. Germ-free mouse experiments and direct IPA supplementation (via drinking water) recapitulated the anti-metastatic phenotype, establishing IPA as sufficient to confer protection.

Mechanistically, IPA acted primarily on bone marrow myelopoiesis. Flow cytometry and single-cell transcriptomic analyses showed that IPA redirected common myeloid progenitor (CMP) fate away from Ly6C-high CCR2+ monocytes — a well-characterized immunosuppressive population — toward the macrophage lineage. This shift reduced circulating immunosuppressive monocytes without directly altering lymphoid cell numbers. The consequence was enhanced CD4+ T cell Th1 differentiation and improved spatial co-localization of CD4+ and CD8+ T cells within the metastatic liver microenvironment, amplifying anti-tumor cytotoxic responses.

In a clinical cohort of chemo-naïve CRC patients, plasma IPA levels increased after chemotherapy in a subset of patients, and circulating IPA concentrations inversely correlated with monocyte abundance (r = −0.42, p < 0.05). Patients with high pre-treatment monocyte levels had significantly reduced disease-free survival, aligning with the mechanistic mouse data. These translational findings position IPA as a clinically measurable biomarker and potential therapeutic adjuvant. The authors propose that IPA supplementation could normalize pathological myelopoiesis, reduce monocyte-driven immunosuppression, and prevent metastatic relapse — particularly in patients who fail to mount sufficient IPA responses to chemotherapy.